Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen R Buttigieg

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Bio-Protocol|October 31, 2017
Construction of FWPV Chimaeric MVAKaren R Buttigieg, Michael A Skinner
Plos One|March 14, 2014
A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse modelKaren R Buttigieg, Stuart D Dowall, Stephen Findlay-Wilson, et al.
Nature Protocols|April 24, 2021
Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assaysKevin R Bewley, Naomi S Coombes, Luc Gagnon, et al.
British Journal of Pharmacology|October 30, 2020
Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrationsJulia A Tree, Jeremy E Turnbull, Karen R Buttigieg, et al.
Nature Communications|August 23, 2020
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interactionMonir Ejemel, Qi Li, Shurong Hou, et al.
Nature Communications|September 23, 2021
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19Jiandong Huo, Halina Mikolajek, Audrey Le Bas, et al.
Nature Structural & Molecular Biology|October 16, 2020
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiangdong Huo, Audrey Le Bas, Reinis R Ruza, et al.
Nature Structural & Molecular Biology|July 15, 2020
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiandong Huo, Audrey Le Bas, Reinis R Ruza, et al.
Nature Structural & Molecular Biology|August 2, 2020
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patientDaming Zhou, Helen M E Duyvesteyn, Cheng-Pin Chen, et al.
ACS Central Science|June 1, 2022
Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 InteractionScott E Guimond, Courtney J Mycroft-West, Neha S Gandhi, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Bio-Protocol|October 31, 2017
Construction of FWPV Chimaeric MVAKaren R Buttigieg, Michael A Skinner
Plos One|March 14, 2014
A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse modelKaren R Buttigieg, Stuart D Dowall, Stephen Findlay-Wilson, et al.
Nature Protocols|April 24, 2021
Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assaysKevin R Bewley, Naomi S Coombes, Luc Gagnon, et al.
British Journal of Pharmacology|October 30, 2020
Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrationsJulia A Tree, Jeremy E Turnbull, Karen R Buttigieg, et al.
Nature Communications|August 23, 2020
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interactionMonir Ejemel, Qi Li, Shurong Hou, et al.
Nature Communications|September 23, 2021
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19Jiandong Huo, Halina Mikolajek, Audrey Le Bas, et al.
Nature Structural & Molecular Biology|October 16, 2020
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiangdong Huo, Audrey Le Bas, Reinis R Ruza, et al.
Nature Structural & Molecular Biology|July 15, 2020
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiandong Huo, Audrey Le Bas, Reinis R Ruza, et al.
Nature Structural & Molecular Biology|August 2, 2020
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patientDaming Zhou, Helen M E Duyvesteyn, Cheng-Pin Chen, et al.
ACS Central Science|June 1, 2022
Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 InteractionScott E Guimond, Courtney J Mycroft-West, Neha S Gandhi, et al.
Pageof 2